Ifosfamide nephrotoxicity: Limited influence of metabolism and mode of administration during repeated therapy in paediatrics

European Journal of Cancer Part A

Volumn 32, Issue 7, 1996, Pages 1179-1184

  Boddy, A V ^a   English, M ^a   Pearson, A D J ^a   Idle, J R ^a   Skinner, R ^a  

^a NEWCASTLE UNIVERSITY   (United Kingdom)

Author keywords

ifosfamide nephrotoxicity; metabolism; pharmacokinetics

Indexed keywords

CREATININE; CYCLOPHOSPHAMIDE; IFOSFAMIDE;

ADOLESCENT; ARTICLE; CHILD; CLINICAL ARTICLE; CREATININE BLOOD LEVEL; DRUG METABOLISM; FANCONI RENOTUBULAR SYNDROME; FEMALE; HUMAN; INFANT; KIDNEY FUNCTION; MALE; NEPHROTOXICITY; PRIORITY JOURNAL;

EID: 0030176402     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/0959-8049(96)00019-6     Document Type: Article

References (40)

1. 1. Pratt CB. Current studies of ifosfamide for pediatric solid tumors and leukemia in the United States. Semin Oncol 1992, 19, 43-50.
2. 2. Chang TKH, Weber GF, Crespi CL, Waxman DJ. Differential activation of cyclophosphamide and ifosphamide by cytochromes P-450 2B and 3A in human liver microsomes. Cancer Res 1993, 53, 5629-5637.
3. 3. Walker D, Flinois J-P, Monkman SC, et al. Identification of the major human hepatic cytochrome P450 involved in activation and N-dechloroethylation of ifosfamide. Biochem Pharmacol 1994, 47, 1157-1163.
4. 4. Sladek N. Metabolism of oxazaphosphorines. Pharmacol Ther 1988, 37, 301-355.
5. 5. Dockham PA, Lee M-O, Sladek NE. Identification of human liver aldehyde dehydrogenases that catalyze the oxidation of aldophosphamide and retinaldehyde. Biochem Pharmacol 1992, 43, 2453-2469.
6. 6. Boddy AV, Yule SM, Wyllie R, Price L, Pearson ADJ, Idle JR. Pharmacokinetics and metabolism in children of ifosfamide administered as a continuous infusion. Cancer Res 1993, 53, 3758-3764.
7. 7. Mohrmann M, Pauli A, Ritzer M, Schönfeld B, Seifert B, Brandis M. Inhibition of sodium-dependent transport systems in LLC-PK1 cells by metabolites of ifosfamide. Renal Physiol Biochem 1992, 15, 289-301.
8. 8. Sood C, O'Brien PJ. Molecular mechanisms of chloroacetaldehyde-induced cytotoxicity in isolated rat hepatocytes. Biochem Pharmacol 1993, 46, 1621-1626.
9. 9. Spengler SJ, Singer B. Formation of interstand cross-links in chloroacetaldehyde-treated DNA demonstrated by ethidium bromide fluorescence. Cancer Res 1988, 48, 4804-4806.
10. 10. Kurowski V, Wagner T. Comparative pharmacokinetics of ifosfamide, 4-hydroxyifosfamide, chloroacetaldehyde and 2- and 3-dechloroethylifosfamide in patients on fractionated intravenous ifosfamide therapy. Cancer Chemother Pharmacol 1993, 33, 36-42.
11. 11. Boddy AV, Cole M, Pearson ADJ, Idle JR. The kinetics of the auto-induction of ifosfamide metabolism during continuous infusion. Cancer Chemother Pharmacol 1995, 36, 53-60.
12. 12. Boddy AV, Yule SM, Wyllie R, Price L, Pearson ADJ, Idle JR. Comparison of continuous infusion and bolus administration of ifosfamide in children. Eur J Cancer 1995, 31A, 785-790.
13. 13. Brock N, Pohl J, Stekar J. Studies on the urotoxicity of oxazaphosphorine cytostatics and its prevention - III: Profile of action of sodium 2-mercaptoethane sulfonate (mesna). Eur J Cancer Clin Oncol 1982, 18, 1377-1387.
14. 14. Cerny T, Küpfer A. The enigma of ifosfamide encephalopathy. Ann Oncol 1992, 3, 679-681.
15. 15. Cerny T, Lind M, Thatcher N, Swindell R, Stout R. A simple outpatient treatment with oral ifosfamide and oral etoposide for patients with small cell lung cancer (SCLC). Br J Cancer 1989, 60, 258-261.
16. 16. Pratt CB, Green AA, Horowitz ME, et al. Central nervous system toxicity following the treatment of pediatric patients with ifosfamide/mesna. J Clin Oncol 1986, 4, 1253-1261.
17. 17. Skinner R, Sharkey IM, Pearson ADJ, Craft AW. Ifosfamide, Mesna and nephrotoxicity in children. J Clin Oncol 1993, 11, 173-190.
18. 18. Boddy AV, Yule SM, Wyllie R, Price L, Pearson ADJ, Idle JR. Intrasubject variation in children of ifosfamide pharmacokinetics and metabolism during repeated administration. Cancer Chemother Pharmacol, in press.
19. 19. Boddy AV, Idle JR. Combined thin-layer chromatography-photography-densitometry for the quantification of ifosfamide and its principal metabolites in urine, cerebrospinal fluid and plasma. J Chromatogr Biomed Appl 1992, 575, 137-142.
20. 20. Skinner R, Pearson ADJ, Coulthard G, et al. Assessment of chemotherapy-associated nephrotoxicity in children with cancer. Cancer Chemother Pharmacol 1991, 28, 81-92.
21. 21. Defronzo RA, Abeloff M, Braine G, Humphrey RL, Davis PJ. Renal dysfunction after treatment with isophosphamide (NSC-109724). Cancer Chemother Rep 1974, 58, 375-382.
22. 22. Suarez A, McDowell H, Niaudet P, Comoy E, Flamant F. Long-term follow-up of ifosfamide renal toxicity in children treated for malignant mesenchymal tumors: an International Society of Pediatric Oncology report. J Clin Oncol 1991, 9, 2177-2182.
23. 23. Heney D, Lewis I, Bailey C. Acute ifosfamide-induced tubular toxicity. Lancet 1989, 2, 103-104.
24. 24. Patterson WP, Khojasteh A. Ifosfamide-induced renal tubular defects. Cancer 1989, 63, 649-651.
25. 25. Beckwith C, Flaharty KK, Cheung AK, Beatty PG. Fanconi's syndrome due to ifosfamide. Bone Marrow Transplant 1993, 11, 71-73.
26. 26. De Schepper J, Stevens G, Verboven M, et al. Ifosfamide-induced Fanconi's syndrome with growth failure in a 2-year-old child. Am J Pediatr Hematol Oncol 1991, 13, 39-41.
27. 27. Goren MP, Wright RK, Horowitz ME, Pratt CB. Ifosfamide-induced subclinical tubular nephrotoxicity despite mesna. Cancer Treat Rep 1987, 71, 127-130.
28. 28. Rossi R, Danzebrink S, Hillebrand D, Linnenburger K, Ullrich K, Jurgens H. Ifosfamide-induced subclinical nephrotoxicity and its potentiation by cisplatinum. Med Pediatr Oncol 1994, 22, 27-32.
29. 29. Al Sheyyab M, Worthington D, Beetham R, Stevens M. The assessment of subclinical ifosfamide-induced renal tubular toxicity using urinary excretion of retinol-binding protein. Pediatr Hematol Oncol 1993, 10, 119-128.
30. 30. Skinner R, Pearson A, Price L, Wyllie R, Coulthard M, Craft A. Ifosfamide nephrotoxicity in children: risk factors and the long term outcome. Med Pediatr Oncol 1994, 23, 265.
31. 31. Colvin M. The comparative pharmacology of cyclophosphamide and ifosfamide. Semin Oncol 1982, 9, 2-7.
32. 32. Tasso MJ, Boddy AV, Price L, Wyllie RA, Pearson ADJ, Idle JR. Pharmacokinetics and metabolism of cyclophosphamide in paediatric patients. Cancer Chemother Pharmacol 1992, 30, 207-211.
33. 33. Yule SM, Boddy AV, Cole M, et al. Cyclophosphamide metabolism in children. Cancer Res 1995, 55, 803.
34. 34. Goren MP, Wright RK, Pratt CB, Pell FE. Dechloroethylation of ifosfamide and neurotoxicity. Lancet 1986, ii, 1219-1220.
35. 35. Ullrich KJ, Rumrich G, David C, Gritzsch DG. Bisubstrates: substances that interact with both renal contraluminal organic anion and organic cation transport systems. II. Zwitterions. Pflugers Arch Eur J Physiol 1993, 425, 300-312.
36. 36. Heney D, Wheeldon J, Rushworth P, Chapman C, Lewis IJ, Bailey CC. Progressive renal toxicity due to ifosfamide. Arch Dis Child 1991, 66, 966-970.
37. 37. Murray GI, Barnes TS, Sewell HF, Ewen SW, Melvin WT, Burke MD. The immunocytochemical localization and distribution of cytochrome-P-450 in normal human hepatic and extrahepatic tissues with a monoclonal-antibody to human cytochrome-P-450. Br J Clin Pharmacol 1988, 25, 465-475.
38. 38. Schuetz EG, Schuetz JD, Grogan WM, et al. Expression of cytochrome P450 3A in amphibian, rat and human kidney. Arch Biochem Biophys 1992, 294, 206-214.
39. 39. Walker D, Ranu HK, Pearson ADJ, Idle JR. Cytochrome P450 CYP3A5 makes a significant contribution to the metabolism in vitro of cyclophosphamide and ifosfamide. Proc Am Soc Cancer Res 1995, 36, 373.
40. 40. Boddy AV, Proctor M, Simmonds D, Lind MJ, Idle JR. Pharmacokinetics, metabolism and clinical effect of ifosfamide in breast cancer patients. Eur J Cancer 1995, 31A, 69-76.